Please assess the completion status of the following clinical trial:

Trial Title: Practical Telemedicine to Improve Control and Engagement for Veterans With Clinic-Refractory Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans with persistently poorly-controlled type 2 diabetes mellitus defined as the presence of 2 HbA1c values 8.5% during the prior year (none \<8.5%) despite 1 or more appointments with a VHA Primary Care Provider (PCP) or Endocrinology during this period.~Exclusion Criteria:~* age \>70~* life expectancy \<5 years, or other comorbidities that would offset the benefits of HbA1c \<8.5%~* inability to communicate by telephone~* dementia or psychosis~* active alcohol/substance disorder~* pregnancy~* prior hypoglycemic seizure/coma~* refusal to perform self-monitored blood glucose (SMBG)~* use of insulin infusion pumps~* hospitalized for stroke, heart attack or had surgery for blocked arteries in the past 12m~* receiving kidney dialysis~* metastatic cancer diagnosis~* use of a continuous blood glucose monitor (due to HT equipment constraints)~* primary provider requests patient not participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PRACTICE-DM (Type: EXPERIMENTAL): PRACTICE-DM is a comprehensive telemedicine intervention that bundles telemonitoring, self-management support, diet/activity support, medication management, and depression support - each of which targets a critical factor underlying PPDM - into a single, comprehensive program specifically developed for practical delivery using existing VHA Home Telehealth (HT) workforce, infrastructure, and technical resources.
- Standard VA Home Telehealth (Type: ACTIVE_COMPARATOR): Standard VA HT care coordination and telemonitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).